Bitcoin price today: slips below $113k, near 6-wk low despite Fed cut bets
Ori Gutwerg, Senior Vice President of Generics at ANI Pharmaceuticals (NASDAQ:ANIP), recently executed a series of stock transactions, according to a filing with the Securities and Exchange Commission. On March 5, Gutwerg sold a total of 5,384 shares of ANI Pharmaceuticals common stock. These sales were conducted at prices ranging from $60.00 to $60.03 per share, resulting in a total transaction value of approximately $323,049. The stock currently trades near $60.62, with the company commanding a market capitalization of $1.23 billion. According to InvestingPro data, analysts maintain a bullish outlook with a consensus target suggesting up to 35% potential upside.
In addition to the sales, Gutwerg also exercised stock options to acquire 300 shares at a price of $31.49 per share, totaling $9,447. Following these transactions, Gutwerg’s direct ownership stands at 94,092 shares. These moves are part of routine transactions and provide insights into the executive’s current holdings in the company. InvestingPro analysis shows ANI Pharmaceuticals maintains strong financial health with a "GREAT" overall score, while delivering impressive revenue growth of 26.2% in the last twelve months.
In other recent news, ANI Pharmaceuticals reported fourth-quarter earnings that exceeded analyst expectations, with adjusted earnings per share reaching $1.63, surpassing the projected $1.45. The company also reported revenue of $190.6 million, outperforming the consensus estimate of $175.12 million and marking a 44.8% increase year-over-year. The Rare Disease segment was a significant growth driver, with revenue more than doubling to $87 million, including $59.4 million from Cortrophin Gel. Following these results, Leerink Partners raised their price target for ANI Pharmaceuticals to $82, maintaining an Outperform rating. The firm highlighted the company’s upward revision of its 2025 revenue and adjusted EBITDA guidance, emphasizing the strong outlook for Cortrophin Gel. Additionally, ANI Pharmaceuticals announced plans to launch a pre-filled syringe formulation of Cortrophin Gel in the second quarter of 2025. Meanwhile, Truist Securities maintained a Hold rating on ANI Pharmaceuticals, with a price target of $62, noting the company’s strategic rebranding efforts within its Rare Disease and Brands segment. These developments reflect ANI Pharmaceuticals’ ongoing transformation and strategic growth initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.